> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Generics Office Expands In-person Meetings
- URL: https://www.fdaweb.com/generics-office-expands-in-person-meetings/
- Published: 2023-09-29T12:00:00.000Z
- Updated: 2026-09-14T18:59:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155455

CDER’s Office of Generic Drugs (OGD) is expanding its post-pandemic return to in-person face-to-face (FTF) meetings with industry. Beginning 10/2, OGD will add the following meetings to the current FTF meeting option for the pre-ANDA product development and pre-submission meetings:

- pre-submission product-specific guidance (PSG) meetings
- post-submission PSG meetings
- enhanced mid-cycle review meetings
- post-complete response letter (CRL) scientific meetings

OGD also says it will offer a videoconference format for:

- PSG teleconferences (t-cons)
- mid-cycle review meetings
- post-CRL clarification t-cons

“The availability of in-person FTF meetings may be limited by facility capacity and logistical considerations,” OGD says. “Meetings that otherwise are granted but that cannot be offered in an in-person FTF format will be conducted via videoconference.” Requests for an in-person FTF meeting must be part of the initial meeting request package received on or after 10/2.